目的:观察金龙胶囊对提高晚期非小细胞肺癌(NSCLC)患者化疗临床受益反应率、改善免疫功能、降低不良反应率的影响。方法:将经病理学检查确诊的56例ⅢB期和Ⅳ期的NSCLC患者随机分为2组,单纯化疗组(对照组)和化疗联合金龙胶囊组(治疗组)各28例。所有患者至少完成3个周期化疗,3周期后观察患者临床受益反应率、免疫功能、不良反应发生率。结果:治疗组体重≥7%者15例,占53.5%(15/28),对照组体重≥7%者13例,占46.4%(13/28),两组比较无显著性差异(P>0.05)。治疗组Karnofsky评分提高≥20分者16例,占57.1%(16/28),对照组Karnofsky评分提高≥20分者10例,占35.7%(10/28),两组比较有显著性差异(P<0.05)。治疗组吗啡类止痛药用量减少≥50%者13例,占46.4%(13/28),对照组吗啡类止痛药用量减少≥50%者7例,占25%(7/28),两组比较有显著性差异(P<0.05)。治疗组不良反应发生率57.1%,对照组75%,两组比较有显著性差异(P<0.05)。结论:金龙胶囊联合化疗治疗晚期NSCLC患者的临床受益率较高,能显著改善患者对化疗的耐受性,提高其用药依从性,且安全性较好,值得推广。 Objective: To observe the effects of Jinlong Capsule in improving the clinical benefit response rate, improving the immune function and reducing the adverse reaction rate in patients with advanced non-small cell lung cancer (NSCLC). Methods: Fifty-six NSCLC patients with stage ⅢB and Ⅳ diagnosed by pathology were randomly divided into two groups, 28 cases in each group. The chemotherapy alone group (control group) and chemotherapy combined with Jinlong Capsule group (treatment group). All patients completed at least three cycles of chemotherapy, three cycles after the observation of clinical benefit response rate, immune function, the incidence of adverse reactions. Results: In the treatment group, 15 cases (53.5%) had weight ≥7% and 13% (≥7%) in the control group, accounting for 46.4% (13/28), there was no significant difference between the two groups (P> 0.05). In the treatment group, Karnofsky score increased by 20 points or more in 16 cases (57.1%, 16/28). In the control group, Karnofsky score increased by 20 points or more (20 cases), accounting for 35.7% (10/28). There was significant difference between the two groups P <0.05). In the treatment group, morphine analgesic dosage reduced by 50%, 13 cases (46.4%), morphine analgesic dosage reduced by 50% (7 cases), control group (25%, 7/28) There was significant difference between the two groups (P <0.05). The incidence of adverse reactions in the treatment group was 57.1% and in the control group 75%, there was significant difference between the two groups (P <0.05). Conclusion: The clinical benefit rate of Jinlong Capsule combined with chemotherapy in patients with advanced NSCLC is high, which can significantly improve the patients’ tolerance to chemotherapy and improve their compliance with medication, which is safe and worthy of promotion.